X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ASTRAZENECA PHARMA VENUS REMEDIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x -821.4 91.9 - View Chart
P/BV x 0.2 13.1 1.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ASTRAZENECA PHARMA
Mar-14
VENUS REMEDIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs2181,285 17.0%   
Low Rs82634 12.9%   
Sales per share (Unadj.) Rs365.6189.6 192.8%  
Earnings per share (Unadj.) Rs1.5-0.2 -729.9%  
Cash flow per share (Unadj.) Rs37.93.8 986.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.568.6 557.3%  
Shares outstanding (eoy) m11.4425.00 45.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.45.1 8.1%   
Avg P/E ratio x101.0-4,712.7 -2.1%  
P/CF ratio (eoy) x4.0249.6 1.6%  
Price / Book Value ratio x0.414.0 2.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,71723,988 7.2%   
No. of employees `0001.01.6 65.4%   
Total wages/salary Rs m3241,605 20.2%   
Avg. sales/employee Rs Th4,100.73,040.2 134.9%   
Avg. wages/employee Rs Th318.01,029.2 30.9%   
Avg. net profit/employee Rs Th16.7-3.3 -510.5%   
INCOME DATA
Net Sales Rs m4,1834,740 88.2%  
Other income Rs m2092 21.8%   
Total revenues Rs m4,2034,832 87.0%   
Gross profit Rs m812-130 -625.3%  
Depreciation Rs m417101 411.9%   
Interest Rs m3800-   
Profit before tax Rs m35-139 -25.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m185 355.6%   
Profit after tax Rs m17-5 -334.0%  
Gross profit margin %19.4-2.7 -708.5%  
Effective tax rate %51.6-3.7 -1,407.2%   
Net profit margin %0.4-0.1 -378.5%  
BALANCE SHEET DATA
Current assets Rs m2,7712,726 101.6%   
Current liabilities Rs m1,9312,435 79.3%   
Net working cap to sales %20.16.1 326.4%  
Current ratio x1.41.1 128.1%  
Inventory Days Days12574 169.6%  
Debtors Days Days5441 131.9%  
Net fixed assets Rs m5,3281,035 514.7%   
Share capital Rs m11450 228.8%   
"Free" reserves Rs m4,177942 443.2%   
Net worth Rs m4,3761,716 255.0%   
Long term debt Rs m1,9110-   
Total assets Rs m8,4284,156 202.8%  
Interest coverage x1.1NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.1 43.5%   
Return on assets %4.7-0.1 -3,844.1%  
Return on equity %0.4-0.3 -131.0%  
Return on capital %6.60-  
Exports to sales %05.7 0.0%   
Imports to sales %20.56.5 317.5%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs m858306 280.2%   
Fx inflow Rs m0375 0.0%   
Fx outflow Rs m858470 182.6%   
Net fx Rs m-858-96 898.3%   
CASH FLOW
From Operations Rs m469-8 -5,787.7%  
From Investments Rs m29-146 -20.0%  
From Financial Activity Rs m-464862 -53.8%  
Net Cashflow Rs m35709 4.9%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 0.3 60.0%  
FIIs % 0.6 15.7 3.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 9.1 729.7%  
Shareholders   20,121 12,856 156.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 23, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS